Experimental CAR-T therapy targets tough lymphoma in early trial

NCT ID NCT07382817

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This early-phase study tests a new treatment called JV-394 for people with T/NK cell lymphoma that has come back or not responded to standard therapy. JV-394 is made from a patient's own immune cells, which are modified to attack cancer cells. The main goal is to find a safe dose and watch for side effects in 33 adult participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JV-394 (a type of CAR-T cell therapy made from the patient's own immune cells)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat T/NK cell lymphoma.
What could go wrong: This is a very early Phase 1 trial with only 33 participants, so it may not work or could cause serious side effects. The therapy is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, Extranodal NK-T-Cell neoplasm T-cell and NK-cell neoplasm T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.